Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ganesh Radhakrishna

Showing results (41-50 of 45) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 45 results.
Eclinicalmedicine|October 3, 2022
Use of a non-endoscopic immunocytological device (Cytosponge™) for post chemoradiotherapy surveillance in patients with oesophageal cancer in the UK (CYTOFLOC): A multicentre feasibility studyChristopher M Jones, Heather O'Connor, Maria O'Donovan, et al.
BMC Cancer|June 29, 2026
Pre-operative proton versus photon-based chemoradiotherapy as an addition to best systemic therapy in the management of oesophageal cancer: protocol for the UK multi-centre randomised phase 2 PROTIEUS studyGanesh Radhakrishna, Christopher M Jones, C William Bleaney, et al.
European Journal of Cancer (Oxford, England : 1990)|July 26, 2024
Standard or high dose chemoradiotherapy, with or without the protease inhibitor nelfinavir, in patients with locally advanced pancreatic cancer: The phase 1/randomised phase 2 SCALOP-2 trialSomnath Mukherjee, Cathy Qi, Rachel Shaw, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|May 5, 2022
Treatment planning comparison in the PROTECT-trial randomising proton versus photon beam therapy in oesophageal cancer: Results from eight European centresLone Hoffmann, Hanna Mortensen, Muhammad Shamshad, et al.
The British Journal of Radiology|February 28, 2022
Estimating the percentage of patients who might benefit from proton beam therapy instead of X-ray radiotherapyNeil G Burnet, Thomas Mee, Simona Gaito, et al.
Pageof 5

Showing results (41-50 of 45) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 45 results.
Eclinicalmedicine|October 3, 2022
Use of a non-endoscopic immunocytological device (Cytosponge™) for post chemoradiotherapy surveillance in patients with oesophageal cancer in the UK (CYTOFLOC): A multicentre feasibility studyChristopher M Jones, Heather O'Connor, Maria O'Donovan, et al.
BMC Cancer|June 29, 2026
Pre-operative proton versus photon-based chemoradiotherapy as an addition to best systemic therapy in the management of oesophageal cancer: protocol for the UK multi-centre randomised phase 2 PROTIEUS studyGanesh Radhakrishna, Christopher M Jones, C William Bleaney, et al.
European Journal of Cancer (Oxford, England : 1990)|July 26, 2024
Standard or high dose chemoradiotherapy, with or without the protease inhibitor nelfinavir, in patients with locally advanced pancreatic cancer: The phase 1/randomised phase 2 SCALOP-2 trialSomnath Mukherjee, Cathy Qi, Rachel Shaw, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|May 5, 2022
Treatment planning comparison in the PROTECT-trial randomising proton versus photon beam therapy in oesophageal cancer: Results from eight European centresLone Hoffmann, Hanna Mortensen, Muhammad Shamshad, et al.
The British Journal of Radiology|February 28, 2022
Estimating the percentage of patients who might benefit from proton beam therapy instead of X-ray radiotherapyNeil G Burnet, Thomas Mee, Simona Gaito, et al.
Pageof 5